ACSL5

Summary

ACSL5 (acyl-CoA synthetase long chain family member 5, HGNC:16526) is a protein-coding gene on chromosome 10q25.2, encoding Long-chain-fatty-acid–CoA ligase 5 (Q9ULC5). Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation.

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme is highly expressed in uterus and spleen, and in trace amounts in normal brain, but has markedly increased levels in malignant gliomas. This gene functions in mediating fatty acid-induced glioma cell growth. Three transcript variants encoding two different isoforms have been found for this gene.

Source: NCBI Gene 51703 — RefSeq curated summary.

At a glance

• Gene–disease (curated): diarrhea 13 (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 121 total — 2 pathogenic
• GTEx eGene: eQTL in 18 tissues, sQTL in 12 (q < 0.05)
• Phenotypes (HPO): 9
• ChEMBL bioactivity: 3 clinical-phase molecules tested; no curated mechanism-of-action drug
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.70 (unconstrained)
• MANE Select transcript: NM_203379
• Interaction hub: 1,752 STRING partners (top 10% of genes corpus-wide)
• Notable: 121 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16526
Approved symbol	ACSL5
Name	acyl-CoA synthetase long chain family member 5
Location	10q25.2
Locus type	gene with protein product
Status	Approved
Aliases	ACS5, ACS2
Ensembl gene	ENSG00000197142
Ensembl biotype	protein_coding
OMIM	605677
Entrez	51703

Gene structure

Transcript identifiers

Ensembl transcripts: 46 — 36 protein_coding, 8 nonsense_mediated_decay, 2 retained_intron

MANE Select: ENST00000354655

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 3, TSL 3: 1, TSL 5: 2

ENST00000354655, ENST00000354273, ENST00000356116, ENST00000393081, ENST00000433418, ENST00000467340, ENST00000495539, ENST00000496328, ENST00000861349, ENST00000861350, ENST00000861351, ENST00000861352, ENST00000861353, ENST00000861354, ENST00000861355, ENST00000861356, ENST00000861357, ENST00000861358, ENST00000861359, ENST00000861360, ENST00000861361, ENST00000861362, ENST00000861363, ENST00000861364, ENST00000861365, ENST00000861366, ENST00000861367, ENST00000861368, ENST00000861369, ENST00000954829, ENST00000954830, ENST00000954831, ENST00000954832, ENST00000954833, ENST00000954834, ENST00000954835, ENST00000954836, ENST00000954837, ENST00000993474, ENST00000993475, ENST00000993477, ENST00001043417, ENST00001043419, ENST00001043420, ENST00001043421, ENST00001138580

RefSeq mRNA: 4 — MANE Select: NM_203379 NM_001387037, NM_016234, NM_203379, NM_203380

CCDS: CCDS7572, CCDS7573, CCDS91344

Canonical transcript exons

ENST00000354655 — 21 exons

Exon	Start	End
ENSE00000724257	112409507	112409685
ENSE00001000193	112411456	112411529
ENSE00001096563	112426258	112426359
ENSE00001096573	112421593	112421665
ENSE00001096575	112421947	112422035
ENSE00001096579	112426788	112426859
ENSE00001411902	112374116	112374269
ENSE00001835863	112427218	112428376
ENSE00003470738	112422325	112422441
ENSE00003482344	112416888	112417022
ENSE00003484218	112410463	112410495
ENSE00003492611	112394918	112395102
ENSE00003541113	112413173	112413307
ENSE00003572499	112425338	112425481
ENSE00003589092	112408422	112408521
ENSE00003619593	112411902	112411979
ENSE00003623182	112410584	112410635
ENSE00003638097	112398901	112399009
ENSE00003652803	112404511	112404575
ENSE00003661740	112417846	112417941
ENSE00003671255	112404705	112404806

Expression profiles

Bgee: expression breadth ubiquitous, 267 present calls, max score 99.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.4060 / max 2111.1540, expressed in 1151 samples.

Highest expression (Bgee): jejunal mucosa, ileal mucosa, corpus epididymis, rectum, mucosa of transverse colon.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ACSL5 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 18 tissues and its splicing (sQTL) in 12 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 30 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Adipose Visceral Omentum	sqtl	1.8e-151	-2.04	10:112426866:G:A
Cells EBV-transformed lymphocytes	sqtl	3.1e-114	-2.48	10:112426866:G:A
Whole Blood	eqtl	2.4e-112	-0.45	10:112384081:G:T
Colon Transverse	sqtl	4.1e-107	+2.16	10:112439529:G:A
Liver	sqtl	1.4e-92	-2.31	10:112426866:G:A
Small Intestine Terminal Ileum	sqtl	3.6e-43	-2.52	10:112426866:G:A
Lung	sqtl	6.8e-10	+0.89	10:112426866:G:A
Testis	eqtl	1.8e-09	-0.30	10:112413796:G:A
Brain Cerebellum	eqtl	5.1e-08	+0.30	10:112381487:T:G
Whole Blood	sqtl	6.6e-06	+0.67	10:112426866:G:A
Cells Cultured fibroblasts	eqtl	7.9e-06	+0.17	10:112375255:C:T
Brain Cerebellar Hemisphere	eqtl	1.9e-05	+0.24	10:112406990:C:T
Nerve Tibial	eqtl	4.0e-05	+0.14	10:112381487:T:G
Esophagus Mucosa	eqtl	6.3e-05	-0.19	10:112325616:C:A
Pancreas	eqtl	6.4e-05	+0.24	10:112348992:T:G
Adrenal Gland	eqtl	7.6e-05	+0.33	10:112350219:A:G
Brain Putamen basal ganglia	eqtl	3.8e-04	+0.18	10:112373303:G:C
Stomach	eqtl	4.4e-04	+0.12	10:112335173:A:G
Brain Hippocampus	eqtl	4.5e-04	+0.18	10:112364188:C:G
Breast Mammary Tissue	sqtl	4.6e-04	+0.72	10:112393875:A:G

FANTOM5 promoters

showing 10 of 28 alternative TSS:

Promoter ID	TPM avg	Samples expressed
107050	15.4339	1057
107037	1.8070	79
107051	1.5061	328
107036	1.0733	53
107041	1.0643	273
107042	0.8578	220
107052	0.2445	44
107060	0.2000	41
107040	0.1686	65
107043	0.1630	61

Top tissues by expression

showing 100 of 281 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.90	gold quality
ileal mucosa	UBERON:0000331	99.27	gold quality
corpus epididymis	UBERON:0004359	99.12	gold quality
rectum	UBERON:0001052	98.47	gold quality
mucosa of transverse colon	UBERON:0004991	98.18	gold quality
colonic mucosa	UBERON:0000317	97.97	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.73	gold quality
duodenum	UBERON:0002114	97.37	gold quality
right lobe of liver	UBERON:0001114	96.43	gold quality
endometrium	UBERON:0001295	96.17	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.08	gold quality
small intestine	UBERON:0002108	95.40	gold quality
right uterine tube	UBERON:0001302	94.83	gold quality
liver	UBERON:0002107	94.60	gold quality
granulocyte	CL:0000094	94.46	gold quality
transverse colon	UBERON:0001157	94.27	gold quality
caput epididymis	UBERON:0004358	94.14	gold quality
upper lobe of left lung	UBERON:0008952	93.38	gold quality
upper lobe of lung	UBERON:0008948	93.28	gold quality
vermiform appendix	UBERON:0001154	93.04	gold quality
gall bladder	UBERON:0002110	92.54	gold quality
monocyte	CL:0000576	92.30	gold quality
leukocyte	CL:0000738	92.25	gold quality
mononuclear cell	CL:0000842	92.13	gold quality
colonic epithelium	UBERON:0000397	91.90	gold quality
intestine	UBERON:0000160	91.46	gold quality
caecum	UBERON:0001153	91.41	gold quality
right lung	UBERON:0002167	91.21	gold quality
lower lobe of lung	UBERON:0008949	91.12	gold quality
omental fat pad	UBERON:0010414	91.03	gold quality
peritoneum	UBERON:0002358	91.02	gold quality
spleen	UBERON:0002106	90.49	gold quality
adipose tissue of abdominal region	UBERON:0007808	90.49	gold quality
cauda epididymis	UBERON:0004360	90.43	gold quality
urinary bladder	UBERON:0001255	90.36	gold quality
large intestine	UBERON:0000059	90.20	gold quality
nasal cavity epithelium	UBERON:0005384	90.11	gold quality
lung	UBERON:0002048	90.10	gold quality
lymph node	UBERON:0000029	89.85	gold quality
colon	UBERON:0001155	89.84	gold quality
blood	UBERON:0000178	88.67	gold quality
visceral pleura	UBERON:0002401	88.44	gold quality
body of stomach	UBERON:0001161	88.36	gold quality
subcutaneous adipose tissue	UBERON:0002190	88.36	gold quality
fallopian tube	UBERON:0003889	88.14	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	87.90	gold quality
adipose tissue	UBERON:0001013	87.44	gold quality
uterus	UBERON:0000995	87.38	gold quality
mucosa of urinary bladder	UBERON:0001259	87.20	gold quality
jejunum	UBERON:0002115	87.11	gold quality
stomach	UBERON:0000945	86.77	gold quality
connective tissue	UBERON:0002384	86.59	gold quality
oviduct epithelium	UBERON:0004804	86.48	gold quality
palpebral conjunctiva	UBERON:0001812	86.41	gold quality
pleura	UBERON:0000977	86.39	gold quality
nasal cavity mucosa	UBERON:0001826	86.30	gold quality
epithelial cell of pancreas	CL:0000083	86.24	gold quality
parietal pleura	UBERON:0002400	85.68	gold quality
epithelium of nasopharynx	UBERON:0001951	85.56	gold quality
bone marrow	UBERON:0002371	85.37	gold quality
sperm	CL:0000019	85.22	gold quality
bone marrow cell	CL:0002092	84.76	gold quality
left uterine tube	UBERON:0001303	84.41	gold quality
left ovary	UBERON:0002119	84.09	gold quality
female reproductive system	UBERON:0000474	84.01	gold quality
seminal vesicle	UBERON:0000998	83.59	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	83.49	gold quality
pancreatic ductal cell	CL:0002079	83.32	silver quality
mucosa of stomach	UBERON:0001199	83.21	gold quality
male germ cell	CL:0000015	83.15	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.13	gold quality
endothelial cell	CL:0000115	83.09	gold quality
smooth muscle tissue	UBERON:0001135	83.03	gold quality
mucosa of paranasal sinus	UBERON:0005030	83.02	gold quality
prostate gland	UBERON:0002367	83.00	gold quality
endocervix	UBERON:0000458	82.86	gold quality
right ovary	UBERON:0002118	82.82	gold quality
body of uterus	UBERON:0009853	82.62	gold quality
superficial temporal artery	UBERON:0001614	82.54	gold quality
cervix squamous epithelium	UBERON:0006922	82.41	gold quality
left testis	UBERON:0004533	82.30	gold quality
bronchial epithelial cell	CL:0002328	82.10	gold quality
fundus of stomach	UBERON:0001160	82.01	gold quality
calcaneal tendon	UBERON:0003701	81.85	gold quality
apex of heart	UBERON:0002098	81.80	gold quality
vagina	UBERON:0000996	81.72	gold quality
metanephros cortex	UBERON:0010533	81.53	gold quality
ovary	UBERON:0000992	81.48	gold quality
right testis	UBERON:0004534	81.32	gold quality
testis	UBERON:0000473	81.29	gold quality
buccal mucosa cell	CL:0002336	81.25	silver quality
spinal cord	UBERON:0002240	81.21	gold quality
thoracic mammary gland	UBERON:0005200	81.13	gold quality
tonsil	UBERON:0002372	81.08	gold quality
epithelium of bronchus	UBERON:0002031	81.05	gold quality
mammary gland	UBERON:0001911	81.01	gold quality
left coronary artery	UBERON:0001626	80.98	gold quality
germinal epithelium of ovary	UBERON:0001304	80.93	gold quality
heart left ventricle	UBERON:0002084	80.89	gold quality
right atrium auricular region	UBERON:0006631	80.86	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	51.69
E-ANND-3	yes	18.62
E-MTAB-6142	no	121.28

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 77 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Small intestine	tissue	405.8	high
Duodenum	tissue	347.8	high
Epididymis	tissue	211.6	high
Liver	tissue	159.5	high
Rectum	tissue	111.9	high
Colon	tissue	107.2	high
Urinary bladder	tissue	71.8	medium
Cervix	tissue	48.9	low
Fallopian tube	tissue	42.6	high
Stomach 1	tissue	42.1	low
Frontal cortex	tissue	40.5
Lung	tissue	34.0	high
Endometrium 1	tissue	28.7	high
Appendix	tissue	28.1	medium
Lymph node	tissue	26.8	not detected
Tonsil	tissue	26.8	not detected
Spleen	tissue	24.6	not detected
Breast	tissue	20.3	not detected
Gallbladder	tissue	20.3	medium
Seminal vesicle	tissue	19.2	low
Adipose tissue	tissue	17.9	not detected
Caudate putamen	tissue	17.7
Bone marrow	tissue	15.7	not detected
Thymus	tissue	15.4
Smooth muscle	tissue	14.6	not detected
Ovary	tissue	12.6	not detected
Prostate	tissue	11.6	not detected
Spinal cord	tissue	10.8
Testis	tissue	9.2	low
Substantia nigra	tissue	9.1
Superior colliculi	tissue	9.0
Tongue	tissue	8.3
Placenta	tissue	8.1	not detected
Esophagus	tissue	7.5	not detected
Locus coeruleus	tissue	7.5
Medulla oblongata	tissue	7.4
Pons	tissue	7.3
Hippocampus	tissue	7.3	not detected
Vagina	tissue	7.2	not detected
Postcentral gyrus	tissue	7.1
Midbrain	tissue	6.9
Thalamus	tissue	6.9
Hypothalamus	tissue	6.8
Kidney	tissue	6.8	medium
Heart muscle	tissue	6.7	not detected
Periaqueductal gray	tissue	6.7
Corpus callosum	tissue	6.5
Septum	tissue	6.3
Putamen	tissue	6.0
Nucleus accumbens	tissue	5.6
Cerebral cortex	tissue	5.5	not detected
Insular cortex	tissue	5.5
Salivary gland	tissue	5.3	not detected
Pancreas	tissue	5.3	low
Ventral forebrain	tissue	5.1
Amygdala	tissue	4.9
Hippocampal formation	tissue	4.9
Entorhinal cortex	tissue	4.9
Temporal cortex	tissue	4.9
Basal ganglia	tissue	4.8	low

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Posterior thalamic nucleus (15.1), Dorsal cochlear nucleus (13.9), Area parastriata, superior (12.3), Nucleus cuneatus (12.3), Cervical spinal cord, ventral horn (11.9).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ERF, FOXO1, MYOD1, SREBF1, TCF12

miRNA regulators (miRDB)

Targeting ACSL5 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 52 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-7161-5P	99.68	68.92	1592
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-548U	99.65	67.78	1463
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-5697	99.39	67.74	1249
HSA-MIR-4460	99.37	68.52	615
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-6507-5P	99.36	70.46	2524
HSA-MIR-4520-2-3P	99.14	69.28	1009

Functional genomics

gnomAD constraint: pLI 1.45e-07, LOEUF 0.702, missense Z 1.25 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000354655 — one region, missense o/e 0.93.

Literature-anchored findings (GeneRIF, showing 35)

• expression of ACS5 in the gastric body and the small intestine with metaplasia or heterotopia (PMID:15736044)
• ACS5 is a very suitable marker molecule for the detection of villus atrophy in the small intestine. (PMID:15809837)
• SREBP-1c-mediated insulin regulation of acyl-CoA synthestase 5 expression indicate that ACS-5 is involved in the anabolic fate of fatty acids. (PMID:16198472)
• Existence of a link between ACSL5 genotype and diet responsiveness. (PMID:17495181)
• Suggest an ACSL5-dependent regulatory mechanism that contributes to the cellular renewal along the crypt-villus axis in human small intestine. (PMID:17681178)
• Oncostatin M directly lowers the plasma triglycerides in hyperlipidemia by stimulating the transcription of ACSL3/5 in the liver. (PMID:17761945)
• Expression of ACSL5 in human epidermis is reported. (PMID:18228202)
• These results indicate that ACSL5 is a critical factor for survival of glioma cells under acidic tumor microenvironment. (PMID:18806831)
• These results reveal a mechanism for elevated transcription of ACSL5 in skeletal muscle of carriers of the rs2419621(T) allele, associated with more rapid diet-induced weight loss. (PMID:19218499)
• Increased ACSL5 is associated with Fatty Liver. (PMID:20470896)
• High ACSL5 transcript levels associate with systemic lupus erythematosus and apoptosis in Jurkat T lymphocytes and peripheral blood cells (PMID:22163040)
• The data strongly indicate that human but not rat acyl-CoA synthetase 5 is sensitive to triacsin C and does not compensate for other triacsin C-sensitive ACSL isoforms. (PMID:22171129)
• Levels of acyl-coenzyme A synthetase 5 in urothelial cells and corresponding neoplasias reflect cellular differentiation. (PMID:23348389)
• Down-regulation of ACSL5 is associated with colorectal cancer. (PMID:24222123)
• Uncoupling of ACSL5 and mitochondrial mortalin by mutated TP53 could be important in colorectal carcinogenesis. (PMID:24770931)
• ACSL5 mediates antiproliferative activities via Wnt2B palmitoylation with diminished Wnt activity. The molecular pathway is probably relevant for intestinal homeostasis, overwhelmed by other pathways in carcinogenesis. (PMID:25356045)
• Functional variant (rs2256368:A>G) affecting ACSL5 exon 20 skipping was identified as a causal factor linked to the migraine-associated rs12355831:A>G, suggesting that the activation of long-chain fatty acids by the spliced ACSL5-Delta20 molecules is involved in migraine pathology. (PMID:27189022)
• colorectal adenocarcinomas with low (n=41; group 1) or high (n=31; group 2) ACSL5 levels were identified. In a one-year follow-up, tumour recurrence was significantly increased in group 1. (PMID:28153554)
• These results suggest that ACSL1, ACSL4 and ACSL5 expression is regulated by ER signaling pathways and ACSL5 is a potential novel biomarker for predicting prognosis of breast cancer patients. (PMID:28498416)
• our study has demonstrated that ACS5 expression was increased in colorectal cancer (CRC) cells and CRC tissues and its upregulation closely correlated to poor tumor differentiation and excess muscular layer in patients with CRC (PMID:28808653)
• rs2419621 T allele carriers are more responsive to lifestyle interventions partly due to an increase in the short ACSL5 protein isoform, increasing cellular, tissue and whole-body fatty acid utilization. (PMID:29605434)
• downregulation of ACSL5 and Wnt2B could play an important role in the development of bronchial-alveolar structures in congenital pulmonary airway malformations (CPAMs). (PMID:30463708)
• Our findings reveal that LOX and ACSL5 are potential prognostic markers for the prognosis of pancreatic cancer patients. (PMID:30712446)
• Our findings indicate that the variant rs2256368:A>G can predict a growth inhibitory activity, caused by the Spl isoform of ACSL5 protein, opposed to the activity of the NSpl. Deep understanding of its functioning might have application in metabolic diseases and cancer. (PMID:31053784)
• miR-497-5p mediates starvation-induced death in colon cancer cells by targeting acyl-CoA synthetase-5 and modulation of lipid metabolism. (PMID:32012265)
• ONECUT2 upregulation is associated with CpG hypomethylation at promoter-proximal DNA in gastric cancer and triggers ACSL5. (PMID:32129880)
• Roles of acyl-CoA synthetase long-chain family member 5 and colony stimulating factor 2 in inhibition of palmitic or stearic acids in lung cancer cell proliferation and metabolism. (PMID:32347412)
• ACYL-CoA synthetase long-chain 5 polymorphism is associated with weight loss and metabolic changes in response to a partial meal-replacement hypocaloric diet.", trans “El polimorfismo de la ACYL-CoA-sintetasa de cadena larga 5 se asocia a perdida de peso y cambios metabolicos en respuesta a una dieta hipocalorica parcial de reemplazo. (PMID:32686444)
• A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. (PMID:32968195)
• Deficiency of acyl-CoA synthetase 5 is associated with a severe and treatable failure to thrive of neonatal onset. (PMID:33191500)
• The gene variant rs2419621 of ACYL-CoA synthetase long-chain 5 gene is associated with weight loss and metabolic changes in response to a robotic sleeve gastrectomy in morbid obese subjects. (PMID:34859867)
• Lysophosphatidylcholine inhibits lung cancer cell proliferation by regulating fatty acid metabolism enzyme long-chain acyl-coenzyme A synthase 5. (PMID:36639836)
• More than just a histone deacetylase: cytoplasmic SIRT6 facilitates fatty acid oxidation through ACSL5 deacetylation. (PMID:36880305)
• Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. (PMID:36932115)
• ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/beta-catenin signaling by palmitoylation modification. (PMID:37131085)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	acsl5	ENSDARG00000075931
mus_musculus	Acsl5	ENSMUSG00000024981
rattus_norvegicus	Acsl5	ENSRNOG00000016265
drosophila_melanogaster	CG3961	FBGN0036821
caenorhabditis_elegans	acs-13	WBGENE00022037

Paralogs (12): ACSL4 (ENSG00000068366), SLC27A5 (ENSG00000083807), ACSBG1 (ENSG00000103740), SLC27A6 (ENSG00000113396), ACSL3 (ENSG00000123983), SLC27A1 (ENSG00000130304), ACSBG2 (ENSG00000130377), SLC27A2 (ENSG00000140284), SLC27A3 (ENSG00000143554), ACSL1 (ENSG00000151726), ACSL6 (ENSG00000164398), SLC27A4 (ENSG00000167114)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1919129) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 17 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased bone mineral density	1
decreased circulating HDL cholesterol level	1
abnormal lens morphology	1
cornea opacity	1
decreased circulating triglyceride level	1
increased heart weight	1
thrombocytopenia	1
decreased liver weight	1
increased spleen weight	1
decreased circulating cholesterol level	1
increased circulating bilirubin level	1
decreased circulating glucose level	1
decreased circulating total protein level	1
abnormal enzyme/coenzyme activity	1
eye hemorrhage	1
decreased bone mineral content	1
shortened QRS complex duration	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Aspergillus fumigatus A1163	B0XWK8	99.9%	Diamond
Aspergillus fumigatus Af293	Q4WYG2	99.9%	Diamond
Pongo abelii	Q5R668	99.7%	Diamond
Arabidopsis thaliana	Q9SS00	91.0%	Diamond
Cavia porcellus	Q9JID6	88.7%	Diamond
Penicillium brevicompactum	P9WEY3	88.0%	Diamond
Penicillium roqueforti FM164	W6R1D9	88.0%	Diamond
Coprinopsis cinerea okayama7#130	A8NS27	78.1%	Diamond
Bacillus subtilis subsp. subtilis str. 168	P23971	76.7%	Diamond
Humulus lupulus	M4ISH1	67.4%	Diamond
Saccharomyces cerevisiae S288C	P30624	61.1%	Diamond
Segniliparus rugosus ATCC BAA-974	E5XP76	58.9%	Diamond
Pseudomonas entomophila L48	Q1IAK8	56.6%	Diamond
Alternaria alternata	C5NN18	47.5%	Diamond
Dictyostelium discoideum	Q55DR6	45.8%	Diamond
Schizosaccharomyces pombe 972h-	O60135	43.3%	Diamond
Streptomyces niveus	Q9L9F6	35.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
LINC02935	ncRNA	107984158
VTI1A	protein-coding	143187
ZDHHC6	protein-coding	64429
MIR6715A	ncRNA	102466189
GPAM	protein-coding	57678
TECTB	protein-coding	6975
MIR6715B	ncRNA	102465427
MIR4295	ncRNA	100422909
TCF7L2	protein-coding	6934

Protein

Protein identifiers

Long-chain-fatty-acid–CoA ligase 5 — Q9ULC5 (reviewed: Q9ULC5)

Alternative names: Arachidonate–CoA ligase, Long-chain acyl-CoA synthetase 5

All UniProt accessions (4): A0A804HIN9, A0A8C8KCK5, A0A8C8L3F5, Q9ULC5

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage. Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids. It was suggested that it may also stimulate fatty acid oxidation. At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells.

Subcellular location. Mitochondrion. Endoplasmic reticulum. Mitochondrion outer membrane. Endoplasmic reticulum membrane. Cell membrane.

Disease relevance. Diarrhea 13 (DIAR13) [MIM:620357] An autosomal recessive disorder characterized by neonatal onset of recurrent vomiting and diarrhea, leading to severe failure to thrive. The disease may be caused by variants affecting the gene represented in this entry.

Miscellaneous. Localize in mitochondrion and endoplasmic reticulum. Localize in mitochondrion and endoplasmic reticulum.

Similarity. Belongs to the ATP-dependent AMP-binding enzyme family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9ULC5-1	1, ACSL5b, ACSL5-fl	yes
Q9ULC5-3	2, ACSL5a
Q9ULC5-4	3, ACSL5delta20

RefSeq proteins (4): NP_001373966, NP_057318, NP_976313, NP_976314 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000873	AMP-dep_synth/lig_dom	Domain
IPR020845	AMP-binding_CS	Conserved_site
IPR042099	ANL_N_sf	Homologous_superfamily
IPR045311	LC-FACS_euk	Family

Pfam: PF00501

Catalyzed reactions (Rhea)

• a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-CoA + AMP + diphosphate (RHEA:15421)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:19713)
• hexadecanoate + ATP + CoA = hexadecanoyl-CoA + AMP + diphosphate (RHEA:30751)
• (9Z)-octadecenoate + ATP + CoA = (9Z)-octadecenoyl-CoA + AMP + diphosphate (RHEA:33607)
• (E)-hexadec-2-enoate + ATP + CoA = (2E)-hexadecenoyl-CoA + AMP + diphosphate (RHEA:36139)
• 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + ATP + CoA = 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoyl-CoA + AMP + diphosphate (RHEA:52012)
• 14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + ATP + CoA = 14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoyl-CoA + AMP + diphosphate (RHEA:52016)
• 5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = 5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:52108)
• 12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + ATP + CoA = 12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:52112)
• 15-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + ATP + CoA = 15-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:52116)

UniProt features (12 total): sequence variant 5, modified residue 2, splice variant 2, chain 1, transmembrane region 1, topological domain 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULC5-F1	90.55	0.69

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Ligase, Metabolic proteins, Predicted membrane proteins, Plasma proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): mitochondria; nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2)

Type	Positions
Phosphoserine	32
N6-acetyllysine	361

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 5; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

5 pathways:

ID	Pathway	Evidence
R-HSA-75876	Synthesis of very long-chain fatty acyl-CoAs	curated
R-HSA-8978868	Fatty acid metabolism	—
R-HSA-75105	Fatty acyl-CoA biosynthesis	—
R-HSA-1430728	Metabolism	—
R-HSA-556833	Metabolism of lipids	—

MSigDB gene sets: 323 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY, GOBP_REGULATION_OF_ORGANIC_ACID_TRANSPORT, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, GOBP_POSITIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, GOBP_POSITIVE_REGULATION_OF_LIPID_TRANSPORT, CEBPB_01

GO Biological Process (6): long-chain fatty acid metabolic process (GO:0001676), positive regulation of long-chain fatty acid import across plasma membrane (GO:0010747), long-chain fatty-acyl-CoA biosynthetic process (GO:0035338), regulation of extrinsic apoptotic signaling pathway (GO:2001236), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (7): long-chain fatty acid-CoA ligase activity (GO:0004467), ATP binding (GO:0005524), arachidonate-CoA ligase activity (GO:0047676), oleoyl-CoA ligase activity (GO:0090434), nucleotide binding (GO:0000166), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (6): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

4 top-level categories:

Category	Pathways
Fatty acyl-CoA biosynthesis	1
Metabolism	1
Fatty acid metabolism	1
Metabolism of lipids	1

GO top-level categories

33 GO namespaces:

Category	Terms
long-chain fatty acid-CoA ligase activity	2
cytoplasm	2
intracellular membrane-bounded organelle	2
fatty acid metabolic process	1
regulation of long-chain fatty acid import across plasma membrane	1
long-chain fatty acid import across plasma membrane	1
positive regulation of transmembrane transport	1
positive regulation of long-chain fatty acid import into cell	1
long-chain fatty-acyl-CoA metabolic process	1
fatty-acyl-CoA biosynthetic process	1
extrinsic apoptotic signaling pathway	1
regulation of apoptotic signaling pathway	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
long-chain fatty acid metabolic process	1
fatty acid-CoA ligase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
mitochondrial membrane	1
organelle outer membrane	1
endomembrane system	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 19 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
long-chain fatty acid metabolic process	BP	direct assay
regulation of extrinsic apoptotic signaling pathway	BP	direct assay
endoplasmic reticulum	CC	direct assay
membrane	CC	high-throughput assay
mitochondrion	CC	direct assay
plasma membrane	CC	direct assay
long-chain fatty acid-CoA ligase activity	MF	direct assay
oleoyl-CoA ligase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,752 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACSL5	ACSS1	Q9NUB1	877
ACSL5	AASDH	Q4L235	867
ACSL5	ACSS2	Q9NR19	848
ACSL5	DGAT1	O75907	815
ACSL5	SLC27A1	Q6PCB7	704
ACSL5	SLC27A2	O14975	697
ACSL5	ABCD1	P33897	658
ACSL5	CD36	P16671	636
ACSL5	ABCD3	P28288	630
ACSL5	ACADM	P11310	617
ACSL5	SCARB2	Q14108	609
ACSL5	SCARB1	Q8WTV0	592
ACSL5	FASN	P49327	583
ACSL5	ABL2	P42684	558
ACSL5	THOC5	Q13769	554

IntAct

Human interaction partners of ACSL5 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

12 partners by confidence:

Partner	Interaction type	MIscore	Records
RETREG3	physical association	0.560	5
AQP6	physical association	0.560	3
EBAG9	physical association	0.560	3
PEX12	physical association	0.560	3
SELI	physical association	0.560	3
SLC10A1	physical association	0.560	3
SLC10A6	physical association	0.560	3
SLC16A7	physical association	0.560	3
SLC35C2	physical association	0.560	3
SLC7A14	physical association	0.560	3
TMEM14B	physical association	0.560	3
CREB3	physical association	0.370	1

BioGRID (42 interactions; top human partners by supporting records): USP29 (Affinity Capture-Western; 4 records), ACAA1 (FRET), AQP6 (Two-hybrid), CAV2 (Affinity Capture-MS), COQ9 (Affinity Capture-MS), CREB3 (Two-hybrid), EBAG9 (Two-hybrid), ELK1 (Affinity Capture-MS), EPT1 (Two-hybrid), FAM134C (Two-hybrid), FAM136A (Affinity Capture-MS), FBXO7 (Biochemical Activity), KIF11 (Affinity Capture-MS), PAK1 (Affinity Capture-MS), PARP2 (Proximity Label-MS)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
ACSL5	“up-regulates quantity”	“long-chain fatty acyl-CoA(4-)”	“chemical modification”
ACSL5	“down-regulates quantity”	“long-chain fatty acid anion”	“chemical modification”

Disease & clinical

Genetic variants

Variant evidence for ACSL5: 121 ClinVar records (2 pathogenic / likely pathogenic); 9 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

121 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	85
Likely benign	10
Benign	4

Top pathogenic / likely-pathogenic (2)

Showing all 2 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
1527599	GRCh37/hg19 10q24.32-25.3(chr10:104030479-115410590)x1	Pathogenic	criteria provided, single submitter	1
2500167	NM_203379.2(ACSL5):c.1358C>A (p.Thr453Lys)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore ACSL5’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 38 predictions of 1,762):

Position(s)	Effect	Δscore	Sites
10:112374270	donor_loss	1.0000
10:112409505–112409506	acceptor_loss	1.0000	6
10:112410444	acceptor_gain	1.0000
10:112410460	acceptor_gain	1.0000
10:112413171–112413172	acceptor_loss	1.0000	6
10:112413303	donor_gain	1.0000
10:112413308–112413309	donor_loss	1.0000	5
10:112421591–112421592	acceptor_loss	1.0000	6
10:112421666–112421667	donor_loss	1.0000	5
10:112422323–112422324	acceptor_loss	1.0000	6

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Rectum Adenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Pancreatic Adenocarcinoma (TCGA)	unfavorable	0.000584

Disease associations

OMIM: gene MIM:605677 | disease phenotypes: MIM:620357

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
diarrhea 13	Limited	Unknown	2

Mondo (1): diarrhea 13 (MONDO:0957253)

HPO phenotypes

9 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0001397	Hepatic steatosis
HP:0001508	Failure to thrive
HP:0001988	Recurrent hypoglycemia
HP:0002013	Vomiting
HP:0002910	Elevated circulating hepatic transaminase concentration
HP:0003073	Hypoalbuminemia
HP:0003623	Neonatal onset
HP:0005208	Secretory diarrhea

GWAS associations

9 associations:

Study	Trait	p-value
GCST90002395_578	Mean platelet volume	6e-26
GCST004599_9	Mean platelet volume	1e-24
GCST90002395_577	Mean platelet volume	3e-18
GCST90002380_83	Basophil percentage of white cells	7e-12
GCST004599_10	Mean platelet volume	1e-11
GCST90002395_576	Mean platelet volume	2e-11
GCST010857_1	Amyotrophic lateral sclerosis	8e-11
GCST90002402_175	Platelet count	3e-10
GCST008949_1	High chromosomal aberration frequency (chromosome type) in genotoxic compound exposure	3e-6

EFO canonical traits (from GWAS)

3 canonical traits:

EFO ID	Trait name
EFO:0009861	chromosome-type aberration frequency
EFO:0007992	basophil percentage of leukocytes
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105818 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 12,907 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

3 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL3301622	GILTERITINIB	4	2,542
CHEMBL491473	CEDIRANIB	3	9,464
CHEMBL1088752	LOSMAPIMOD	3	901

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

2 measured of 4 human assays (184 total across all organisms); most potent 2 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL4761388	IC50	69000 nM
CHEMBL4776019	IC50	114000 nM

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.10	Kd	8	nM	CEDIRANIB
6.68	Kd	208	nM	GILTERITINIB
5.77	Kd	1690	nM	LOSMAPIMOD

PubChem BioAssay actives

3 with measured affinity, of 181 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline	1424897: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0080	uM
Gilteritinib	1424897: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.2080	uM
6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide	1424897: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	1.6900	uM

CTD chemical–gene interactions

67 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	5
Acetaminophen	increases expression, decreases expression	4
Benzo(a)pyrene	affects expression, affects methylation, decreases expression	4
Tetrachlorodibenzodioxin	decreases expression, increases expression, affects expression	4
Cyclosporine	decreases expression, increases expression	3
GW 7647	affects cotreatment, increases expression	2
Estradiol	affects cotreatment, decreases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	decreases expression, increases expression	2
Palmitic Acid	affects response to substance, affects abundance, decreases expression, increases expression	2
aristolochic acid I	increases expression	1
afuresertib	increases expression	1
3,19-(2-bromobenzylidene)andrographolide	decreases expression, decreases response to substance	1
bisphenol F	increases expression	1
sotorasib	affects cotreatment, increases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases activity, increases expression, affects binding	1
bisphenol A	decreases expression	1
deoxynivalenol	decreases expression	1
ascorbate-2-phosphate	increases expression, affects binding, affects cotreatment	1
beta-lapachone	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	increases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
ochratoxin A	decreases expression	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3991610	Binding	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by ma	The target landscape of clinical kinase drugs. — *Science*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for ACSL5 across ~30M SureChEMBL compounds — explore on Sugi Predict.